The peptide information landscape mixes commercial catalogues, forum posts, and social claims with primary records scattered across regulator databases, trial registries, journals, and chemical databases. The atlas was built to make those layers traceable without turning visibility into endorsement.
The editorial workflow is documented in Evidence grading, Scope and selection, Dose language, and Identity and structure assets.
- Scope entries.
- Resolve identity.
- Search authoritative sources.
- Grade exact claims.
- Separate jurisdiction status.
- Validate structure and citations.
- Apply dated refresh.
Guardrails: no invented identifiers; market sources only prove marketing; preserve the safety-language boundary.
What the atlas is
This is an evidence-first research atlas, not a product directory. Its entries cover regulator-approved active substances, clinical-stage candidates, An entry with substantial scientific visibility or identity value. Biological rationale and non-human evidence do not establish patient benefit. 定義の出典: Scope and selection methodology · 用語集 or laboratory peptides, An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. 定義の出典: Scope and selection methodology · 用語集 names, and explicit boundary cases. Inclusion reflects scientific, clinical, regulatory, or public visibility—not approval, benefit, quality, or suitability.
Each layer answers a different question:
| Layer | Atlas question | Primary artifact | What it cannot establish |
|---|---|---|---|
| Identity | What exact entity does the name describe? | Identity record, identifiers, and provenance sidecar | That a physical sample matches the record |
| Evidence | How well does the evidence support this exact claim? | Evidence-by-claim and key-studies rows | Approval, quality, or suitability |
| Approval/status | Is a named product authorized for a use in a jurisdiction? | Dated jurisdiction table and official record | Support for every claim about the molecule |
| Safety | What label risks, study signals, and unknowns are documented? | Label-scoped and evidence-qualified safety sections | Individual risk or a product guarantee |
| Product quality | What identity, purity, sterility, and manufacturing evidence exists? | Product-quality record and cited testing standard | That one result establishes every quality attribute |
| Coverage | Are required pages and fields present? | Generated coverage report | Scientific validity or current truth |
Pipeline
The production loop begins by defining scope, then resolves identity before searching authoritative sources. Editors grade exact claims, keep jurisdictional status separate, validate structures and citations, and attach dates so time-sensitive records can be refreshed.
The tirzepatide and BPC-157 monographs show why order matters: a molecule can carry different grades for different claims, while its regulatory and product-quality records remain separate.
Rules
Primary and authoritative sources take priority: current regulator records, official labels, trial registries, peer-reviewed human studies, recognized identity databases, pharmacopoeial standards, and statutes or agency guidance. Reviews can orient a search, but they cannot be the only support for a decisive efficacy, safety, or legal-status claim.
Market sources have a narrower role. They can show that a name or mixture is marketed; they cannot establish clinical benefit, safety, identity, purity, sterility, or legal status. Editors do not invent identifiers, trial numbers, label statements, sequences, approvals, or jurisdictional rules when verification fails.
Identity boundaries are preserved. TB-500 can refer to materially different entities; GHK-Cu has a database-asset caveat; thymalin and cerebrolysin are mixtures without one sequence or depiction. Recording that uncertainty is more accurate than forcing each name into a single-substance template.
Snapshot
SNAPSHOT — verified 2026-08-08. The generated coverage report records 100 catalog entries, 100 monographs, and 118,893 monograph words. Counts describe the frozen corpus at that date; they are not an evergreen scientific conclusion.
The snapshot spans eight editorial categories and six recorded entry types: 58 approved drugs, one approved diagnostic, 13 A clinical-stage candidate with scientific or public relevance. Investigation is not approval, and a studied exposure is not a recommendation. 定義の出典: Scope and selection methodology · 用語集 entries, 15 An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. 定義の出典: Scope and selection methodology · 用語集 entries, six An entry with substantial scientific visibility or identity value. Biological rationale and non-human evidence do not establish patient benefit. 定義の出典: Scope and selection methodology · 用語集 entries, and seven boundary cases. These totals sum to the catalog; they do not rank the entries or validate their claims.
Limits
Coverage checks can confirm that a page exists, required sections are present, identifiers have the expected form, and cited URLs are recorded. They cannot prove that a paper supports a sentence, that a database record matches a sample, or that a time-sensitive status remains current after the verification date.
That is why every material conclusion must stay bounded by exact identity, claim, product, jurisdiction, and date. Readers can audit those layers through the source rows and the companion guide, How to read peptide evidence.
Why it matters
The atlas is useful because uncertainty remains visible. Approved status does not make every claim grade A; a grade does not establish approval; online visibility does not establish product quality; and a complete page does not guarantee correctness.
The meta point is a workflow, not a catalog count: separate the questions, cite the decisive record, preserve ambiguity, state the verification date, and make each conclusion no broader than its evidence.